VBI Vaccines Inc.   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Cambridge MA United States (2001)

Organization Overview

First Clinical Trial
2006
NCT04531098
First Marketed Drug
2021
hepatitis b vaccine (recombinant) (Recombivax)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Variation Biotechnologies Inc. | VBI Vaccines | VBI Vaccines (Delaware), Inc. | VBI Vaccines Inc.

Active Ingredients

Marketed Drugs (1)

hepatitis b vaccine (recombinant) (Recombivax) (2021)

Drugs in Phase 4 Trials (1)

hepatitis b vaccine (recombinant) (Recombivax) (5 trials)

Drugs in Phase 2 Trials (3)

brii-179 (1 trial)

interferon alfa-1b (Rebif) (1 trial)

vir-2218 (1 trial)

Drugs in Phase 1 Trials (5)

vbi-1501 (1 trial)

vbi-1901 (1 trial)

vbi-2901a (2 trials)

vbi-2902a (1 trial)

vbi-2905a (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cytomegalovirus Infections (Phase 1)

Glioblastoma (Phase 1)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis B (Phase 4)

Infections (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 9